Portola Pharmaceuticals, Inc. (PTLA) Shares Sold by Hanseatic Management Services Inc.
Hanseatic Management Services Inc. decreased its holdings in shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) by 76.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,417 shares of the biopharmaceutical company’s stock after selling 17,383 shares during the quarter. Hanseatic Management Services Inc.’s holdings in Portola Pharmaceuticals were worth $293,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds have also modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Portola Pharmaceuticals by 14.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,078 shares of the biopharmaceutical company’s stock valued at $117,000 after buying an additional 258 shares in the last quarter. Jacobi Capital Management LLC purchased a new position in shares of Portola Pharmaceuticals during the second quarter valued at $125,000. IFP Advisors Inc grew its holdings in shares of Portola Pharmaceuticals by 7.7% during the second quarter. IFP Advisors Inc now owns 2,370 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 170 shares in the last quarter. QS Investors LLC purchased a new position in Portola Pharmaceuticals in the second quarter valued at about $147,000. Finally, Canada Pension Plan Investment Board purchased a new position in Portola Pharmaceuticals in the third quarter valued at about $178,000. Institutional investors and hedge funds own 86.04% of the company’s stock.
PTLA has been the topic of a number of recent research reports. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $80.00 target price on shares of Portola Pharmaceuticals in a research note on Wednesday, September 6th. BidaskClub downgraded Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 19th. Zacks Investment Research downgraded Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Credit Suisse Group set a $70.00 target price on Portola Pharmaceuticals and gave the company a “hold” rating in a research note on Thursday, August 10th. They noted that the move was a valuation call. Finally, Morgan Stanley restated an “overweight” rating and issued a $81.00 target price (up previously from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $65.15.
Shares of Portola Pharmaceuticals, Inc. (PTLA) traded up $1.06 during trading hours on Thursday, hitting $49.55. The company’s stock had a trading volume of 157,012 shares, compared to its average volume of 991,225. Portola Pharmaceuticals, Inc. has a 12 month low of $17.15 and a 12 month high of $67.10. The company has a quick ratio of 8.31, a current ratio of 8.31 and a debt-to-equity ratio of 0.24.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.08. Portola Pharmaceuticals had a negative return on equity of 110.46% and a negative net margin of 938.19%. The company had revenue of $3.83 million during the quarter, compared to analysts’ expectations of $4.71 million. During the same quarter in the previous year, the firm earned ($1.64) earnings per share. The business’s quarterly revenue was down 58.9% compared to the same quarter last year. analysts predict that Portola Pharmaceuticals, Inc. will post -4.95 EPS for the current fiscal year.
Portola Pharmaceuticals Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Stock Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.